A drug company with a costly treatment for kidney patients is under federal investigation. The Competition Bureau alleges Otsuka Canada Pharmaceutical Inc. of Saint-Laurent, Que. acted to “prevent or delay generic versions of this product from coming to market”.
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
